<div id="readability-page-1"><div><ul><li>SOPHiA GENETICS SA , is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025</li><li>The Rolle Vaud-based company is expected to report a 14.3% increase in revenue to $18.125 million from $15.85 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.</li><li>​LSEG's mean analyst estimate for SOPHiA GENETICS SA is for a loss of 24 cents per share. </li><li>The current average analyst rating on the shares is &#34;strong buy&#34; and the breakdown of recommendations is 4 &#34;strong buy&#34; or &#34;buy,&#34; no &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for SOPHiA GENETICS SA is $6.00, about 13.5% above its last closing price of $5.19</li></ul>Previous quarterly performance (using preferred earnings measure in US dollars). ​<div><table><tbody><tr><td>QUARTER ENDING</td><td>STARMINESMARTESTIMATE®</td><td>LSEG IBES ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td><td>SURPRISE %</td></tr><tr><td>Jun. 30 2025</td><td>-0.23</td><td>-0.23</td><td>-0.33</td><td>Missed</td><td>-43.5</td></tr><tr><td>Mar. 31 2025</td><td>-0.26</td><td>-0.25</td><td>-0.26</td><td>Missed</td><td>-5.1</td></tr><tr><td>Dec. 31 2024</td><td>-0.25</td><td>-0.22</td><td>-0.23</td><td>Missed</td><td>-2.7​</td></tr><tr><td>Sep. 30 2024</td><td>-0.24</td><td>-0.23</td><td>-0.28</td><td>Missed</td><td>-21.7</td></tr><tr><td>​​Jun. 30 2024</td><td>-0.28</td><td>-0.28</td><td>-0.23</td><td>Beat</td><td>18.6</td></tr><tr><td>Mar. 31 2024</td><td>-0.27</td><td>-0.27</td><td>-0.21</td><td>Beat</td><td>23.2​</td></tr><tr><td>Dec. 31 2023</td><td>-0.25</td><td>-0.27</td><td>-0.37</td><td>Missed</td><td>-37</td></tr><tr><td>Sep. 30 2023</td><td>-0.33</td><td>-0.32</td><td>-0.21</td><td>Beat</td><td>35.1</td></tr></tbody></table></div>This summary was machine generated October 31 at 14:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</div></div>

SOPH

SOPHiA GENETICS SA is expected to report a quarterly revenue increase of 14.3% to $18.125 million for the period ending September 30, 2025, despite an anticipated loss of 24 cents per share. The average analyst rating is "strong buy" with a median 12-month price target of $6.00, reflecting a 13.5% upside from the last closing price of $5.19. Recent performance shows mixed results, with several earnings misses and beats in previous quarters.

SOPHiA GENETICS SA expected to post a loss of 24 cents a share - Earnings Preview